Effect of hepatitis B and C clearance on atazanavir exposure

Eur J Clin Pharmacol. 2015 Nov;71(11):1409-11. doi: 10.1007/s00228-015-1926-8. Epub 2015 Aug 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antiviral Agents / blood
  • Antiviral Agents / pharmacokinetics*
  • Antiviral Agents / therapeutic use
  • Atazanavir Sulfate / blood
  • Atazanavir Sulfate / pharmacokinetics*
  • Atazanavir Sulfate / therapeutic use
  • HIV Infections / drug therapy
  • HIV Infections / metabolism*
  • Hepatitis B / drug therapy
  • Hepatitis B / metabolism*
  • Hepatitis C / drug therapy
  • Hepatitis C / metabolism*
  • Humans
  • Male
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use

Substances

  • Antiviral Agents
  • Oligopeptides
  • Atazanavir Sulfate
  • telaprevir